chartexchange

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc. | Oct 1, 2026 4:05 PM EDT

WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia’s common stock on September 30, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Read original article